Advances in allergen-specific immunotherapy

Bibliography

• NOON L, CANTAB BC: Prophylactic inoculation against hay fever. Lancet (1911) 177:1572–1573.
   Google Scholar
• AKDIS CA, AKDIS M, BLESKEN T et al.: Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. an. Invest. (1996) 98:1676–1683.
   PubMed Web of Science ®Google Scholar
• TAYLOR A, VERHAGEN J, AKDIS CA, AKDIS M: T regulatory cells in allergy and health: a question of allergen specificity and balance. Int. Arch. Allergy Immunol (2004) 135:73–82.
   PubMed Web of Science ®Google Scholar
• ROMAGNANI P, ANNUNZIATO F, PICCINNI MP, MAGGI E, ROMAGNANI S: Cytokines and chemokines in T lymphopoiesis and T-cell effector function. Immunol Today (2000) 21:416–418.
   PubMedGoogle Scholar
• PRESCOTT SL, MACAUBAS C, HOLT BJ et al.: Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. J. Immunol (1998) 160:4730–4737.
   PubMed Web of Science ®Google Scholar
• PRESCOTT SL, MACAUBAS C, SMALLACOMBE T, HOLT BJ, SLY PD, HOLT PG: Development of allergen-specific T-cell memory in atopic and normal children. Lancet (1999) 353:196–200.
   PubMed Web of Science ®Google Scholar
• YSSEL H, GROUX H: Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases. Int. Arch. Allergy Immunol (2000) 121:10–18.
   PubMed Web of Science ®Google Scholar
• TRAUTMANN A, AKDIS M, KLEEMANN D et al.: T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J. Clin. Invest. (2000) 106:25–35.
   PubMed Web of Science ®Google Scholar
• AKDIS CA, AKDIS M, TRAUTMANN A, BLASER K: Immune regulation in atopic dermatitis. Curr. Opin. Immunol (2000) 12:641–646.
   PubMed Web of Science ®Google Scholar
• AKDIS M, TRAUTMANN A, KLUNKER S et al.: T helper (Th) 2 predominance in atopic disease is due to preferential apoptosis of circulating memory/effector Thl cells. FASEB J. (2003) 17:1026–1035.
   PubMed Web of Science ®Google Scholar
• ROMAGNANI S: Lymphokine production by human T cells in disease states. Annu. Rev. Immunol (1994) 12:227–257.
   PubMed Web of Science ®Google Scholar
• CORRY DB: IL-13 in allergy: home at last. Curr. Opin. Immunol (1999) 11:610–614.
   PubMed Web of Science ®Google Scholar
• MOVERARE R, ELFMAN L, VESTERINEN E, METSO T, HAAHTELA T: Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy (2002) 57:423–430.
   PubMed Web of Science ®Google Scholar
• BOUSQUET J, LOCKEY R, MALLING HJ et al.: Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Asthma Immunol (1998)
   Google Scholar
• TARZI M, LARCHE M: Peptide immunotherapy for allergic disease. Expert Opin. Biol. Ther. (2003) 3:617–626.
   PubMed Web of Science ®Google Scholar
• ASTORI M, VON GARNIER C, KETTNER A. DUFOUR N, CORRADIN G, SPERTINI F: Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J. Immunol (2000) 165:3497–3505.
   PubMed Web of Science ®Google Scholar
• VRTALA S, HIRTENLEHNER K, SUSANI M et al.: Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J. (2001) 15:2045–2047.
   PubMed Web of Science ®Google Scholar
• •Single amino acid mutations in recombinant allergens lead to hypoallergic variants by altering IgE epitopes.
   Google Scholar
• VRTALA S, AKDIS CA, BUDAK F et al.: T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J. Immunol (2000) 165:6653–6659.
   PubMed Web of Science ®Google Scholar
• LINHART B, JAHN-SCHMID B, VERDINO P et al.: Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J. (2002) 16:1301–1303.
   PubMed Web of Science ®Google Scholar
• FERREIRA F, EBNER C, KRAMER B et al.: Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J. (1998) 12:231–242.
   PubMed Web of Science ®Google Scholar
• MULLER U, AKDIS CA, FRICKER M et al.: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol (1998) 101:747–754.
   PubMed Web of Science ®Google Scholar
• ••This is the first human short T cell epitopepeptide immunotherapy, which shows allergen-specific T cell tolerance and regulation of IgG4 versus IgE ratios in favour of IgG4 1 week after contact with live bee stings.
   Google Scholar
• BALL T, FUCHS T, SPERR WR et ell.: B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J. (1999) 13:1277–1290.
   Google Scholar
• TANG DC, DEVIT M, JOHNSTON SA: Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 356:152–154.
   PubMed Web of Science ®Google Scholar
• RAZE, TIGHE H, SATO Yet al: Preferential induction of a Thl immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. Sci. USA (1996) 93:5141–5145.
   PubMed Web of Science ®Google Scholar
• HSU CH, CHUA KY, TAO MH et al: Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat. Med. (1996) 2:540–544.
   PubMed Web of Science ®Google Scholar
• HARTL A, KIESSLICH J, WEISS R et al.: Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. J. Allergy Clin. Immunol (1999) 103:107–113.
   PubMed Web of Science ®Google Scholar
• KWON SS, KIM N, Y00 TJ: The effect of vaccination with DNA encoding murine T-cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis. Allergy (2001) 56:741–748.
   PubMed Web of Science ®Google Scholar
• SLATER JE, PAUPORE E, ZHANG YT, COLBERG-POLEY AM: The latex allergen Hey b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J. Allergy Clin. Immunol. (1998) 102:469–475.
   PubMed Web of Science ®Google Scholar
• BLACK J: The oral administration of pollen. J. Lab. Clin. Med. (1927) 12:1156.
   Google Scholar
• CANONICA GW, PASSALACQUA G: Noninjection routes for immunotherapy. J. Allergy Clin. Immunol (2003) 111:437–448.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of non-injection imunotherapy.
   Google Scholar
• TARI MG, MANCINO M, MONTI G: Immunotherapy by inhalation of allergen in powder in house dust allergic asthma-a double-blind study. J. Investig Allergol Clin. Immunol (1992) 2:59–67.
   PubMed Web of Science ®Google Scholar
• CRIMI E, VOLTOLINI S, TROISE C et al.: Local immunotherapy with Dermatophagoides extract in asthma. J. Allergy Clin. Immunol. (1991) 87:721–728.
   PubMed Web of Science ®Google Scholar
• MALLING HJ: Is sublingual immunotherapy clinically effective? Curr. Opin. Allergy Clin. Immunol (2002) 2:523–531.
   PubMed Web of Science ®Google Scholar
• PASSALACQUA G, GUERRA L, PASQUALI M, LOMBARDI C, CANONICA GW: Efficacy and safety of Ann. Allergy sublingual immunotherapy. Ann. Allergy Asthma Immunol (2004) 93:3-12; quiz 12–13, 103.
   Google Scholar
• BAHCECILER NN, ARIKAN C, TAYLOR A et al.: Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mite. Int. Arch. Allergy Immunol (2005) 136(3):287–294.
   PubMed Web of Science ®Google Scholar
• IPPOLITI F, DE SANTIS W, VOLTERRANI A et al.: Immunomodulation during sublingual therapy in allergic children. Pediatr. Allergy Immunol (2003) 14:216–221.
   PubMed Web of Science ®Google Scholar
• ARIKAN C, BAHCECILER NN, DENIZ G et al.: Bacillus Calmette-Guerin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin. Exp. Allergy (2004) 34:398–405.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates that BCG vaccine administered together with SLIT induces IL-12 production, without improving clinical outcome.
   Google Scholar
• WANG CC, ROOK GA: Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology (1998) 93:307–313.
   PubMed Web of Science ®Google Scholar
• ZUANY-AMORIM C, SAWICKA E, MANLIUS C et al.: Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. (2002) 8:625–629.
   PubMed Web of Science ®Google Scholar
• AKDIS CA, KUSSEBI F, PULENDRAN B et al.: Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur. j Immunol (2003) 33:2717–2726.
   PubMed Web of Science ®Google Scholar
• •TLR2-triggering immunostimulatory lipopeptides suppress IgE and lung eosinophilia, and induce IFN-y and IL-10 production by T cells.
   Google Scholar
• BOHLE B, BREITWIESER A, ZWOLFER B et al.: A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J. Immunol (2004) 172:6642–6648.
   PubMed Web of Science ®Google Scholar
• SIMONS FE, SHIKISHIMA Y, VAN NEST G, EIDEN JJ, HAYGLASS KT: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol (2004) 113:1144–1151.
   PubMed Web of Science ®Google Scholar
• ••Amb a 1-immunostimulatory DNAsequence conjugate SIT led to a prolonged shift from Th2 immunity towards Thl immunity and appeared to be safe.
   Google Scholar
• KLINMAN DM: Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol (2004) 4:249–258.
   PubMed Web of Science ®Google Scholar
• AKDIS CA, BLASER K: IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. (1999) 13:603–609.
   PubMed Web of Science ®Google Scholar
• AKDIS CA, BLESKEN T, AKDIS M, WIDTHRICH B, BLASER K: Role of IL-10 in specific immunotherapy. j Clin. Invest. (1998) 102:98–106.
   PubMed Web of Science ®Google Scholar
• •This study shows that IL-10 plays a major role in T cell unresponsiveness.
   Google Scholar
• JUTEL M, AKDIS M, BUDAK F et al.: IL-10 and TGF-0 cooperate in regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol (2003) 33:1205–1214.
   PubMed Web of Science ®Google Scholar
• WALKER SM, VARNEY VA, GAGA M, JACOBSON MR, DURHAM SR: Grass pollen immunotherapy: efficacy and safety during a 4-year follow- up study. Allergy (1995) 50:405–413.
   PubMed Web of Science ®Google Scholar
• VARNEY VA, GAGA M, FREW AJ, ABER VR., KAY AB, DURHAM SR: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br. Med. J. (1991) 302:265–269.
   PubMed Web of Science ®Google Scholar
• ROCKLIN RE, SHEFFER AL, GREINEDER DK, MELMON KL: Generation of antigen-specific suppressor cells during allergy desensitization. N Engl. J. Med. (1980) 302:1213–1219.
   PubMed Web of Science ®Google Scholar
• CRETICOS PS, ADKINSON NF JR, KAGEY-SOBOTKA A et al.: Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. j Clin. Invest. (1985) 76:2247–2253.
   PubMed Web of Science ®Google Scholar
• RAK S, LOWHAGEN O, VENGE P: The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J. Allergy Clin. Immunol (1988) 82:470–480.
   PubMed Web of Science ®Google Scholar
• OTSUKA H, MEZAWA A, OHNISHI M, OKUBO K, SEKI H, OKUDA M: Changes in nasal metachromatic cells during allergen immunotherapy. Clin. Exp. Allergy (1991) 21:115–119.
   PubMed Web of Science ®Google Scholar
• FLICKERS, STEINBERGER P, NORDERHAUG Let al.: Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur. J. Immunol (2002) 32:2156–2162.
   Google Scholar
• VAN NEERVEN RJ, WIKBORG T, LUND G et al.: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol (1999) 163:2944–2952.
   PubMed Web of Science ®Google Scholar
• JUTEL M, AKDIS M, BUDAK F et al.: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. j Immunol. (2003) 33:1205–1214.
   PubMed Web of Science ®Google Scholar
• AKDIS CA, BLESKEN T, AKDIS M, WUTHRICH B, BLASER K: Role of interleukin 10 in specific immunotherapy. Clin. Invest. (1998) 102:98–106.
   Google Scholar
• AKDIS M, VERHAGEN J, TAYLOR A et al.: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. (2004) 199:1567–1575.
   PubMed Web of Science ®Google Scholar
• ••One of the key issues in monoallergies is tounderstand why an individual develops an allergy to a single protein, while tolerating thousands of others. Trl cells consistently represent the dominant subset specific for common environmental allergens in healthy individuals; in contrast, there is a high frequency of allergen-specific Th2 cells in allergic individuals.
   Google Scholar
• BORISH L, AARONS A, RUMBYRT J, CVIETUSA P, NEGRI J, WENZEL S: Interleukin-10 regulation in normal subjects and patients with asthma. J. Allergy Clin. Immunol (1996) 97:1288–1296.
   PubMed Web of Science ®Google Scholar
• KONING H, NEIJENS HJ, BAERT MR, ORANJE AP, SAVELKOUL HF: T cells subsets and cytokines in allergic and non-allergic children. II. Analysis and IL-5 and IL-10 mRNA expression and protein production. Cytokine (1997) 9:427–436.
   Google Scholar
• HELLINGS PW, VANDENBERGHE P, KASRAN A et al.: Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. Eur. J. Immunol (2002) 32:585–594.
   PubMed Web of Science ®Google Scholar
• HANEDA K, SANO K, TAMURA G et al.: Transforming growth factor-beta secreted from CD4(+) T cells ameliorates antigen-induced eosinophilic inflammation. A novel high- dose tolerance in the trachea. Am. J. Respir. Cell Md. Biol. (1999) 21:268–274.
   Google Scholar
• STEINBRINK K, WOLFL M, JONULEIT H, KNOP J, ENK AH: Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. (1997) 159:4772–4780.
   PubMed Web of Science ®Google Scholar
• SONODA E, MATSUMOTO R, HITOSHI Yet al.: Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J. Exp. Med. (1989) 170:1415–1420.
   Google Scholar
• JEANNIN P, LECOANET S, DELNESTE Y, GAUCHAT JF, BONNEFOY JY: IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol. (1998) 160:3555–3561.
   PubMed Web of Science ®Google Scholar
• KEHRY MR, YAMASHITA LC: Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing. Proc. Natl. Acad. Sci. USA (1989) 86:7556–7560.
   PubMed Web of Science ®Google Scholar
• ACHATZ G, NITSCHKE L, LAMERS MC: Effect of transmembrane and cytoplasmic domains of IgE on the IgE response. Science (1977) 276:409–411.
   Google Scholar
• ALLAM JP, KLEIN E, BIEBER T, NOVAK N: Transforming growth factor-betal regulates the expression of the high-affinity receptor for IgE on CD34 stem cell-derived CD la dendritic cells in vitro. J. Invest. Dermatol. (2004) 123:676–682.
   PubMed Web of Science ®Google Scholar
• MASTRANDREA F, SERIO G, MINARDI A et al.: IgE responses to Dermatophagoides pteronyssinus native major allergens Der p 1 and Der p 2 during long-term specific immunotherapy. Allergy (1997) 52:1115–1119.
   PubMed Web of Science ®Google Scholar
• PICHLER CE, HELBLING A, PICHLER WJ: Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy (2001) 56:301–306.
   PubMed Web of Science ®Google Scholar
• WALKER C, VIRCHOW JC JR, BRUIJNZEEL PL, BLASER K: T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J. Immunol. (1991) 146:1829–1835.
   PubMed Web of Science ®Google Scholar
• SCHLEIMER RP, DERSE CP, FRIEDMAN B et al.: Regulation of human basophil mediator release by cytokines. I. Interaction with anti-inflammatory steroids. Immunol. (1989) 143:1310–1327.
   Google Scholar
• TRETER S, LUQMAN M: Antigen-specific T cell tolerance down-regulates mast cell responses in vivo. Cell. Immunol. (2000) 206:116–124.
   PubMed Web of Science ®Google Scholar
• SHIM YK, KIM BS, CHO SH, MIN KU, HONG SJ: Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin. Exp. Allergy (2003) 33:52–57.
   PubMed Web of Science ®Google Scholar
• MARSHALL JS, LEAL-BERUMEN I, NIELSEN L, GLIBETIC M, JORDANA M: Interleukin (IL)-10 Inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J. Clin. Invest. (1996) 97:1122–1128.
   PubMed Web of Science ®Google Scholar
• SCHANDANE L, ALONSO-VEGA C, WILLEMS F et al.: B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J. Immunol. (1994) 152:4368–4374.
   PubMed Web of Science ®Google Scholar